Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to discuss future development and potential registration pathways
Related news for (SLRX)
- Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
- MoBot alert highlights: NASDAQ: ACXP, NASDAQ: PCSA, NASDAQ: SLRX, NASDAQ: XTLB, NYSE: BURU (10/07/25 06:00 PM)
- MoBot alert highlights: NASDAQ: SLRX, NASDAQ: GLUE, NASDAQ: DEVS, NASDAQ: CHEK, NYSE: ATCH (09/15/25 07:00 AM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/28/25 07:00 PM
- Hot Stocks in the News – June 17, 2025
